Gilead seeks U.S. approval for COVID-19 treatment remdesivir

By Manojna Maddipatla (Reuters) - Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday

Reuters August 11, 2020 02:06:04 IST
Gilead seeks U.S. approval for COVID-19 treatment remdesivir

COVID-19 treatment remdesivir" src="https://images.firstpost.com/wp-content/uploads/reuters/08-2020/11/2020-08-10T151118Z_1_LYNXNPEG7917B_RTROPTP_2_HEALTH-CORONAVIRUS-EU-GILEAD.jpg" alt="Gilead seeks US approval for COVID19 treatment remdesivir" width="300" height="225" />

By Manojna Maddipatla

(Reuters) - Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday.

The antiviral drug, which helped shorten the hospital recovery time in a U.S. trial, has been at the forefront of the battle against the pandemic after the FDA granted it emergency use authorization (EUA) in May.

The authorization cleared the way for broader use of the drug in more hospitals around the United States, which has recorded over 162,600 COVID-19 deaths and over 5 million infections. But the EUA status is designed to be temporary.

Gilead said its marketing application for remdesivir, to be sold under brand name Veklury, is supported by data from two late-stage trials conducted by the drugmaker and another by the National Institute of Allergy and Infectious Diseases.

Remdesivir has already been approved by multiple regulatory authorities around the world, including in the European Union, Australia and Japan.

The U.S. government has secured nearly all of remdesivir's supply through September. To boost the drug's availability globally, Gilead has signed multiple manufacturing and supply deals, including with Pfizer Inc and Britain's Hikma Pharmaceuticals Plc .

A bipartisan group of state attorneys general urged the U.S. government last week to allow other companies to make remdesivir to increase its availability and lower prices.

Shares of Gilead were down 1.5% in late afternoon trading.

Oppenheimer analyst Hartaj Singh said investors are worried that if Gilead cannot secure full approval until at least by the end of the year, it might not be able to meet 2020 sales estimates for the drug.

"On many occasions, government entities are expressly forbidden from buying or utilizing drugs not approved by the FDA and other regulatory authorities."

Consensus sales expectations for remdesivir are up to $2.2 billion for the year, Singh said, after Gilead raised its full-year sales target last month to include revenue from the drug.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila and Shounak Dasgupta in Bengaluru, Lewis Krauskopf in New York and Shinjini Ganguli in Bengaluru)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

Nine Chinese engineers among 13 killed in 'attack' on bus in northwest Pakistan
World

Nine Chinese engineers among 13 killed in 'attack' on bus in northwest Pakistan

The incident occurred in Dasu area of Upper Kohistan district of Khyber Pakhtunkhwa province where Chinese engineers and construction workers are helping Pakistan build a dam which is part of CPEC

WPI inflation eases to 12.07% in June as food, crude prices soften
Business

WPI inflation eases to 12.07% in June as food, crude prices soften

Inflation in fuel and power basket eased to 32.83 percent during June, against 37.61 percent in May

Pulitzer Prize-winning photojournalist Danish Siddiqui killed in Afghanistan: Politicans, journalists pay tributes
India

Pulitzer Prize-winning photojournalist Danish Siddiqui killed in Afghanistan: Politicans, journalists pay tributes

The Pulitzer prize winner, who was in Kandahar covering operations against Taliban, was killed when he was riding along with the Afghan Special Forces